Completion Axillary Lymph Node Dissection for Identifying pN2–3 Status as an Indication for Adjuvant CDK4/6 Inhibitor
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial
Lancet Oncol 2024 Aug 06;[EPub Ahead of Print], J de Boniface, M Appelgren, R Szulkin, S Alkner, Y Andersson, L Bergkvist, J Frisell, OD Gentilini, M Kontos, T Kühn, D Lundstedt, BV Offersen, RO Bagge, T Reimer, M Sund, P Christiansen, L Rydén, TF Tvedskov,From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.